20 January 2026
Lilly's Sofetabart Mipitecan Gains FDA Breakthrough Status for Platinum-Resistant Ovarian Cancer
FDA grants Breakthrough Therapy status to sofetabart mipitecan for platinum-resistant ovarian cancer, based on promising Phase 1 results. Phase 3 trial underway.